Role for a Web-Based Intervention to Alleviate Distress in People With Newly Diagnosed Testicular Cancer: Mixed Methods Study.
anxiety disorders
cancer survivors
depression
emotional distress
testicular germ cell tumor
Journal
JMIR cancer
ISSN: 2369-1999
Titre abrégé: JMIR Cancer
Pays: Canada
ID NLM: 101666844
Informations de publication
Date de publication:
28 Oct 2022
28 Oct 2022
Historique:
received:
19
05
2022
accepted:
14
09
2022
revised:
24
08
2022
entrez:
28
10
2022
pubmed:
29
10
2022
medline:
29
10
2022
Statut:
epublish
Résumé
Distress is common immediately after diagnosis of testicular cancer. It has historically been difficult to engage people in care models to alleviate distress because of complex factors, including differential coping strategies and influences of social gender norms. Existing support specifically focuses on long-term survivors of testicular cancer, leaving an unmet need for age-appropriate and sex-sensitized support for individuals with distress shortly after diagnosis. We evaluated a web-based intervention, Nuts & Bolts, designed to provide support and alleviate distress after diagnosis of testicular cancer. Using a mixed methods design to evaluate the acceptability, feasibility, and impact of Nuts & Bolts on distress, we randomly assigned participants with recently diagnosed testicular cancer (1:1) access to Nuts & Bolts at the time of consent (early) or alternatively, 1 week later (day 8; delayed). Participants completed serial questionnaires across a 4- to 5-week period to evaluate levels of distress (measured by the National Comprehensive Cancer Network Distress Thermometer [DT]; scored 0-10), anxiety, and depression (Hospital Anxiety and Depression Score [HADS]-Anxiety and HADS-Depression; each scored 0-21). The primary end point was change in distress between consent and day 8. Secondary end points of distress, anxiety, and depression were assessed at defined intervals during follow-up. Optional, semistructured interviews occurring after completion of quantitative assessments were thematically analyzed. Overall, 39 participants were enrolled in this study. The median time from orchidectomy to study consent was 14.8 (range 3-62) days. Moderate or high levels of distress evaluated using DT were reported in 58% (23/39) of participants at consent and reduced to 13% (5/38) after 1 week of observation. Early intervention with Nuts & Bolts did not significantly decrease the mean DT score by day 8 compared with delayed intervention (early: 4.56-2.74 vs delayed: 4.47-2.74; P=.85), who did not yet have access to the website. A higher baseline DT score was significantly predictive of reduction in DT score during this period (P<.001). Median DT, HADS-Anxiety, and HADS-Depression scores reduced between orchidectomy and 3 weeks postoperatively and then remained stable throughout the observation period. Thematic analysis of 16 semistructured interviews revealed 4 key themes, "Nuts & Bolts is a helpful tool," "Maximizing benefits of the website," "Whirlwind of diagnosis and readiness for treatment," and "Primary stressors and worries," as well as multiple subthemes. Distress is common following the diagnosis of testicular cancer; however, it decreases over time. Nuts & Bolts was considered useful, acceptable, and relevant by individuals diagnosed with testicular cancer, with strong support for the intervention rendered by thematic analyses of semistructured interviews. The best time to introduce support, such as Nuts & Bolts, is yet to be determined; however, it may be most beneficial as soon as testicular cancer is strongly suspected or diagnosed.
Sections du résumé
BACKGROUND
BACKGROUND
Distress is common immediately after diagnosis of testicular cancer. It has historically been difficult to engage people in care models to alleviate distress because of complex factors, including differential coping strategies and influences of social gender norms. Existing support specifically focuses on long-term survivors of testicular cancer, leaving an unmet need for age-appropriate and sex-sensitized support for individuals with distress shortly after diagnosis.
OBJECTIVE
OBJECTIVE
We evaluated a web-based intervention, Nuts & Bolts, designed to provide support and alleviate distress after diagnosis of testicular cancer.
METHODS
METHODS
Using a mixed methods design to evaluate the acceptability, feasibility, and impact of Nuts & Bolts on distress, we randomly assigned participants with recently diagnosed testicular cancer (1:1) access to Nuts & Bolts at the time of consent (early) or alternatively, 1 week later (day 8; delayed). Participants completed serial questionnaires across a 4- to 5-week period to evaluate levels of distress (measured by the National Comprehensive Cancer Network Distress Thermometer [DT]; scored 0-10), anxiety, and depression (Hospital Anxiety and Depression Score [HADS]-Anxiety and HADS-Depression; each scored 0-21). The primary end point was change in distress between consent and day 8. Secondary end points of distress, anxiety, and depression were assessed at defined intervals during follow-up. Optional, semistructured interviews occurring after completion of quantitative assessments were thematically analyzed.
RESULTS
RESULTS
Overall, 39 participants were enrolled in this study. The median time from orchidectomy to study consent was 14.8 (range 3-62) days. Moderate or high levels of distress evaluated using DT were reported in 58% (23/39) of participants at consent and reduced to 13% (5/38) after 1 week of observation. Early intervention with Nuts & Bolts did not significantly decrease the mean DT score by day 8 compared with delayed intervention (early: 4.56-2.74 vs delayed: 4.47-2.74; P=.85), who did not yet have access to the website. A higher baseline DT score was significantly predictive of reduction in DT score during this period (P<.001). Median DT, HADS-Anxiety, and HADS-Depression scores reduced between orchidectomy and 3 weeks postoperatively and then remained stable throughout the observation period. Thematic analysis of 16 semistructured interviews revealed 4 key themes, "Nuts & Bolts is a helpful tool," "Maximizing benefits of the website," "Whirlwind of diagnosis and readiness for treatment," and "Primary stressors and worries," as well as multiple subthemes.
CONCLUSIONS
CONCLUSIONS
Distress is common following the diagnosis of testicular cancer; however, it decreases over time. Nuts & Bolts was considered useful, acceptable, and relevant by individuals diagnosed with testicular cancer, with strong support for the intervention rendered by thematic analyses of semistructured interviews. The best time to introduce support, such as Nuts & Bolts, is yet to be determined; however, it may be most beneficial as soon as testicular cancer is strongly suspected or diagnosed.
Identifiants
pubmed: 36306156
pii: v8i4e39725
doi: 10.2196/39725
pmc: PMC9652729
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e39725Informations de copyright
©Ciara Conduit, Christina Guo, Allan B Smith, Orlando Rincones, Olivia Baenziger, Benjamin Thomas, Jeremy Goad, Dan Lenaghan, Nathan Lawrentschuk, Lih-Ming Wong, Niall M Corcoran, Margaret Ross, Peter Gibbs, Sophie O'Haire, Angelyn Anton, Elizabeth Liow, Jeremy Lewin, Ben Tran. Originally published in JMIR Cancer (https://cancer.jmir.org), 28.10.2022.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Psychooncology. 2013 Nov;22(11):2557-64
pubmed: 23825010
Psychooncology. 2011 Feb;20(2):115-26
pubmed: 20336645
Indian J Psychol Med. 2018 May-Jun;40(3):232-238
pubmed: 29875530
N Engl J Med. 2014 Nov 20;371(21):2005-16
pubmed: 25409373
J Natl Compr Canc Netw. 2022 Feb;20(2):167-192
pubmed: 35130500
J Clin Oncol. 2012 Oct 20;30(30):3712-9
pubmed: 23008322
J Adv Nurs. 2005 Mar;49(6):616-23
pubmed: 15737222
Psychol Health Med. 2010 Mar;15(2):146-58
pubmed: 20391232
J Clin Oncol. 2021 May 10;39(14):1553-1562
pubmed: 33729863
Psychooncology. 2018 Apr;27(4):1129-1137
pubmed: 29171109
Support Care Cancer. 2017 Jul;25(7):2285-2296
pubmed: 28281051
Urol Oncol. 2006 Jul-Aug;24(4):279-86
pubmed: 16818179
BMJ. 2021 May 10;373:n972
pubmed: 33972268
J Psychosoc Oncol. 2014;32(3):310-21
pubmed: 24611453
Patient Educ Couns. 2021 Oct;104(10):2480-2489
pubmed: 33741232
Patient Educ Couns. 2006 Dec;64(1-3):142-50
pubmed: 16480847
J Clin Oncol. 2018 May 20;36(15):1505-1512
pubmed: 29617189
Bull World Health Organ. 2001;79(4):373-4
pubmed: 11357217
Psychooncology. 2003 Dec;12(8):814-20
pubmed: 14681954
Support Care Cancer. 2015 Jun;23(6):1679-88
pubmed: 25424520
Psychosom Med. 2014 May;76(4):257-67
pubmed: 24804884
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Eur J Cancer Care (Engl). 2017 Nov;26(6):
pubmed: 28544085
Am J Mens Health. 2016 Jan;10(1):39-58
pubmed: 25389212
J Natl Compr Canc Netw. 2022 Jan;20(1):96-98
pubmed: 34991072
J Urol. 1993 Mar;149(3):498-501
pubmed: 8382321
J Affect Disord. 2002 Sep;71(1-3):1-9
pubmed: 12167495
J Clin Oncol. 2010 Oct 20;28(30):4649-57
pubmed: 20855830
BJU Int. 2013 Jun;111(8):1287-93
pubmed: 23469865
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
Front Endocrinol (Lausanne). 2019 Feb 25;10:113
pubmed: 30858829
Psychooncology. 2009 Jun;18(6):580-8
pubmed: 18855944
BMC Psychiatry. 2010 Dec 30;10:113
pubmed: 21192795
Support Care Cancer. 2012 Nov;20(11):2737-46
pubmed: 22382589
J Cancer Surviv. 2020 Jun;14(3):284-293
pubmed: 31823122
Br J Gen Pract. 2004 Apr;54(501):248-53
pubmed: 15113490
J Med Internet Res. 2016 Aug 23;18(8):e229
pubmed: 27554525
Support Care Cancer. 2007 Mar;15(3):279-86
pubmed: 16944218
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
CA Cancer J Clin. 2008 Jul-Aug;58(4):214-30
pubmed: 18558664
JMIR Cancer. 2018 Jan 15;4(1):e1
pubmed: 29335233
Patient Relat Outcome Meas. 2021 Jun 08;12:129-171
pubmed: 34135651
Br J Cancer. 2011 Nov 8;105 Suppl 1:S1-4
pubmed: 22048027
J Clin Oncol. 2017 Apr 10;35(11):1211-1222
pubmed: 28240972
J Cancer Surviv. 2015 Sep;9(3):541-53
pubmed: 25697335
Cancer Control. 2010 Jan;17(1):44-51
pubmed: 20010518
JAMA. 1999 Feb 10;281(6):537-44
pubmed: 10022110
J Clin Oncol. 2017 Dec 20;35(36):4066-4077
pubmed: 29095681
Cancer Manag Res. 2021 May 11;13:3803-3816
pubmed: 34007213